Inovio resumes VGX-3100 HPV cancer program

Inovio Pharmaceuticals Inc. (NASDAQ:INO) said FDA lifted a clinical hold on its Phase III program of VGX-3100 to treat cervical dysplasia caused by HPV. The company plans to immediately begin a pair of Phase III trials of the candidate.

FDA placed the hold on Inovio’s development program for VGX-3100 last October and requested additional data on the shelf life of the company's redesigned Cellectra electroporation device used to administer the product (see BioCentury, Oct. 31, 2016)...